U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645300) titled 'LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial' on June 08.
Brief Summary: The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Hypertension Treated With Antihypertensive Drugs
Chronic Kidney Disease, 3B and 4
Intervention:
DRUG: phase 2A Chlorthalidone
very low dose...